Allogeneic CAR-T cell therapies: Overcoming clinical challenges and therapeutic potential against tumors.
Off-the-shelf CAR-T cells offer manufacturing advantages but require genetic engineering to overcome immune rejection challenges.
This balanced review evaluates the current state of allogeneic CAR-T cell therapies, examining the advantages of standardized off-the-shelf manufacturing versus the biological challenges of alloreactivity and immune rejection, with a focus on solid tumor applications. Key engineering approaches including TALEN, CRISPR, and transposon-based modifications are discussed alongside early clinical trial data.
What the study was
- Study design
- Narrative review
- Population
- Patients with hematologic and solid tumor malignancies
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Journal of Biomedical Research
Why it surfaced
Timely review of allogeneic CAR-T field with balanced assessment of clinical barriers and opportunities; relevant to T6 pipeline for CAR-T development monitoring.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.